Results 101 to 110 of about 643 (132)
Some of the next articles are maybe not open access.
Biktarvy for the treatment of HIV infection: Progress and prospects
Biochemical Pharmacology, 2023Bictegravir (BIC), a second-generation integrase strand-transfer inhibitor (INSTI) with high resilience to INSTI-resistance mutations, is integrated as a key component of Biktarvy® - a fixed-dose once-daily triple-drug regimen of bictegravir (BIC), emtricitabine (FTC) plus tenofovir alafenamide (TAF). Based on the accumulated evidence from HIV clinical
Guangdi Li, Erik De Clercq
exaly +3 more sources
VILLAINTINA SWITCHES FROM COMPLERA TO GENVOYA TO BIKTARVY
Minnesota Review, 2021exaly +2 more sources
Zulassungsempfehlung für Biktarvy® erteilt.
MMW Fortschritte Der Medizin, 2018exaly +2 more sources
A Novel Case of Biktarvy-Associated Stevens-Johnson Syndrome With Severe Ocular Involvement
Cornea OpenPurpose: The purpose of this study was to describe the first reported case of Stevens-Johnson syndrome (SJS) associated with bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy), highlighting a rare presentation with severe ocular and oral involvement in the absence of cutaneous findings.
Darren G Gregory
exaly +2 more sources
Xenobiotica; the fate of foreign compounds in biological systems, 2023
Bictegravir (BIC) is a potent small-molecule integrase strand-transfer inhibitor (INSTI) and a component of Biktarvy®, a single-tablet combination regimen that is currently approved for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Raju, Subramanian +14 more
openaire +1 more source
Bictegravir (BIC) is a potent small-molecule integrase strand-transfer inhibitor (INSTI) and a component of Biktarvy®, a single-tablet combination regimen that is currently approved for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Raju, Subramanian +14 more
openaire +1 more source